Interna Therapeutics and Daiichi Sankyo Partner to Advance MNM-Based Targeted Delivery Technology
Interna Therapeutics and Daiichi Sankyo collaborate to advance MNM-based targeted delivery technologies, aiming to enhance intracellular delivery, boost therapeutic activity, and improve performance across key drug development programs.
Interna Therapeutics Daiichi Sankyo Collaboration | 17/04/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy